Head to Head Analysis: Blueprint Medicines (BPMC) & Celyad (CYAD)
Blueprint Medicines (NASDAQ: BPMC) and Celyad (NASDAQ:CYAD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.
Earnings and Valuation
This table compares Blueprint Medicines and Celyad’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Blueprint Medicines||$27.77 million||113.77||-$72.49 million||($3.41)||-21.61|
|Celyad||$9.43 million||42.68||-$26.12 million||N/A||N/A|
Insider and Institutional Ownership
83.5% of Blueprint Medicines shares are held by institutional investors. Comparatively, 3.4% of Celyad shares are held by institutional investors. 3.4% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Blueprint Medicines and Celyad’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Blueprint Medicines has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Celyad has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Blueprint Medicines and Celyad, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Blueprint Medicines presently has a consensus price target of $83.78, suggesting a potential upside of 13.70%. Celyad has a consensus price target of $74.00, suggesting a potential upside of 81.46%. Given Celyad’s higher probable upside, analysts clearly believe Celyad is more favorable than Blueprint Medicines.
Celyad beats Blueprint Medicines on 6 of the 11 factors compared between the two stocks.
About Blueprint Medicines
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.